ArticleDiscover oncology2025
Exploring the prognostic value and immune landscape of EGLN1 in colorectal cancer: insights from bioinformatics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a global health burden because of its high mortalities. It is crucial to discover new biomarkers that can help predict the outcome of patients as well as identify new therapeutic targets to improve treatment options for CRC patients. EGLN1, a protein belonging to the family of prolyl hydroxylase domain-containing proteins, has been associated with the progression of various cancer types. However, its involvement in CRC remains uncertain.
methodsWe conducted an analysis of EGLN1 expression levels in colorectal cancer (CRC) tissues using publicly available datasets. EGLN1 expression was also evaluated in relation to patient survival. To explore the potential biological functions and signaling pathways associated with EGLN, we performed gene set enrichment analysis (GSEA). We also investigated the immune landscape of EGLN1 in CRC by examining its association with immune infiltration and immune-related markers.
resultsWe consistently observed a significant decrease in EGLN1 level in CRC tumor tissues when compared to normal tissues, indicating its potential role as a tumor suppressor gene specific to CRC. The diagnostic potential of EGLN1 was substantiated by its effective discrimination between normal and tumor tissues in patients with CRC. Functional enrichment analysis further uncovered EGLN1's involvement in the regulation of crucial biological processes, cellular components, and molecular functions relevant to CRC development and progression. The correlation analysis revealed the potential immunomodulatory role of EGLN1, affecting immune checkpoint molecules, antigen presentation, and immune cell trafficking within the tumor microenvironment. Additionally, high level of EGLN1 exhibited a significant association with improved recurrence-free survival (RFS) and emerged as an independent prognostic factor. Knockdown experiments demonstrated EGLN1's role in suppressing cell proliferation and migration in CRC.
conclusionIn summary, our findings position EGLN1 as a promising multi-faceted biomarker in CRC, with implications for prognosis, immune microenvironment modulation, and potential therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.